Gsa Capital Partners LLP Catalyst Biosciences, Inc. Transaction History

Gsa Capital Partners LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.91 - $4.16 $159,933 - $731,124	-175,751 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.78 - $5.18 $23,496 - $32,198	6,216 Added 3.67%	175,751 $722,000
Q2 2021 Aug 05, 2021	BUY	$4.1 - $5.33 $588,772 - $765,403	143,603 Added 553.77%	169,535 $734,000
Q1 2021 May 10, 2021	BUY	$4.93 - $7.15 $65,554 - $95,073	13,297 Added 105.24%	25,932 $131,000
Q4 2020 Feb 03, 2021	BUY	$4.55 - $7.29 $57,489 - $92,109	12,635 New	12,635 $80,000
Q1 2020 May 12, 2020	SELL	$3.5 - $8.51 $119,164 - $289,739	-34,047 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$4.52 - $7.91 $153,892 - $269,311	34,047 New	34,047 $232,000
Q3 2019 Nov 12, 2019	SELL	$4.91 - $9.31 $198,982 - $377,297	-40,526 Closed	0 $0
Q2 2019 Aug 06, 2019	BUY	$7.08 - $10.6 $286,924 - $429,575	40,526 New	40,526 $299,000
Q4 2018 Feb 12, 2019	SELL	$6.59 - $11.28 $2.11 Million - $3.61 Million	-319,915 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$9.35 - $12.44 $1.52 Million - $2.02 Million	162,770 Added 103.58%	319,915 $3.45 Million
Q2 2018 Aug 09, 2018	BUY	$9.11 - $28.88 $1.43 Million - $4.54 Million	157,145 New	157,145 $1.83 Million

215

Ticker CBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,477,100
Description
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.